LivaNova PLC (NASDAQ:LIVN) Receives $74.78 Consensus Price Target from Analysts

Shares of LivaNova PLC (NASDAQ:LIVN) have received a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $74.7778.

A number of equities research analysts have issued reports on the stock. Barclays increased their target price on shares of LivaNova from $67.00 to $73.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. The Goldman Sachs Group reissued a “neutral” rating and issued a $66.00 price objective on shares of LivaNova in a research report on Friday, January 9th. Weiss Ratings reissued a “sell (d+)” rating on shares of LivaNova in a research report on Friday, March 27th. Needham & Company LLC increased their price objective on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Finally, Stifel Nicolaus set a $80.00 price objective on shares of LivaNova in a research report on Wednesday, February 25th.

LivaNova Price Performance

LivaNova stock opened at $65.14 on Friday. The firm has a market cap of $3.56 billion, a PE ratio of -14.61 and a beta of 0.97. LivaNova has a 52-week low of $35.00 and a 52-week high of $71.92. The company has a quick ratio of 1.16, a current ratio of 1.36 and a debt-to-equity ratio of 0.29. The company’s 50 day moving average is $64.75 and its two-hundred day moving average is $61.45.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. The company had revenue of $360.92 million for the quarter, compared to analyst estimates of $354.31 million. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The firm’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. On average, research analysts expect that LivaNova will post 3.66 EPS for the current fiscal year.

Institutional Investors Weigh In On LivaNova

A number of large investors have recently modified their holdings of the company. UMB Bank n.a. increased its position in shares of LivaNova by 22.6% in the 4th quarter. UMB Bank n.a. now owns 971 shares of the company’s stock valued at $60,000 after purchasing an additional 179 shares during the last quarter. Hantz Financial Services Inc. grew its position in shares of LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after buying an additional 267 shares during the last quarter. Arizona State Retirement System grew its position in shares of LivaNova by 1.7% in the 3rd quarter. Arizona State Retirement System now owns 16,129 shares of the company’s stock valued at $845,000 after buying an additional 274 shares during the last quarter. Parallel Advisors LLC grew its position in shares of LivaNova by 28.8% in the 4th quarter. Parallel Advisors LLC now owns 1,266 shares of the company’s stock valued at $78,000 after buying an additional 283 shares during the last quarter. Finally, Bayforest Capital Ltd grew its position in shares of LivaNova by 44.8% in the 3rd quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock valued at $48,000 after buying an additional 284 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.